RGLS - Regulus Therapeutics Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.6850
+0.0150 (+2.24%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.6700
Open0.6655
Bid0.6400 x 1000
Ask0.6800 x 1100
Day's Range0.6210 - 0.7199
52 Week Range0.4300 - 1.7400
Volume493,025
Avg. Volume325,696
Market Cap18.912M
Beta (5Y Monthly)1.88
PE Ratio (TTM)N/A
EPS (TTM)-1.0280
Earnings DateAug 06, 2020 - Aug 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.17
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Regulus Therapeutics Reports First Quarter 2020 Financial Results and Recent Updates
    PR Newswire

    Regulus Therapeutics Reports First Quarter 2020 Financial Results and Recent Updates

    Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the first quarter ended March 31, 2020 and provided a corporate update.

  • Regulus (RGLS) Expected to Beat Earnings Estimates: Should You Buy?
    Zacks

    Regulus (RGLS) Expected to Beat Earnings Estimates: Should You Buy?

    Regulus (RGLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Regulus Reports Fourth Quarter and Year-End 2019 Financial Results and Recent Updates
    PR Newswire

    Regulus Reports Fourth Quarter and Year-End 2019 Financial Results and Recent Updates

    Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the fourth quarter and year ended December 31, 2019 and provided a corporate update.

  • Regulus (RGLS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
    Zacks

    Regulus (RGLS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

    Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Regulus Therapeutics Reinitiates Multiple Ascending Dose Study of RGLS4326 for the Treatment of ADPKD
    PR Newswire

    Regulus Therapeutics Reinitiates Multiple Ascending Dose Study of RGLS4326 for the Treatment of ADPKD

    Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it initiated dosing of the second cohort of its Phase 1 multiple ascending dose clinical trial (the "MAD study") of RGLS4326 for the treatment of autosomal dominant polycystic kidney disease (ADPKD). The Company expects to complete this study in mid-2020 with topline results available thereafter. The Company is also planning to initiate a Phase 1b short-term dosing study in patients with ADPKD in the second half of 2020 to evaluate RGLS4326 for safety, pharmacokinetics, and biomarkers of pharmacodynamic activity. RGLS4326 is a novel oligonucleotide designed to inhibit miR-17 and to preferentially target the kidney.

  • How Regulus Therapeutics Inc. (NASDAQ:RGLS) Can Impact Your Portfolio Volatility
    Simply Wall St.

    How Regulus Therapeutics Inc. (NASDAQ:RGLS) Can Impact Your Portfolio Volatility

    If you're interested in Regulus Therapeutics Inc. (NASDAQ:RGLS), then you might want to consider its beta (a measure...

  • Hedge Funds Are Dumping Regulus Therapeutics Inc (RGLS)
    Insider Monkey

    Hedge Funds Are Dumping Regulus Therapeutics Inc (RGLS)

    How do we determine whether Regulus Therapeutics Inc (NASDAQ:RGLS) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. They may not always be right (no one is), but data shows […]

  • Regulus Therapeutics Announces FDA Removal of Partial Clinical Hold for Multiple Ascending Dose Study of RGLS4326
    PR Newswire

    Regulus Therapeutics Announces FDA Removal of Partial Clinical Hold for Multiple Ascending Dose Study of RGLS4326

    Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the U.S. Food and Drug Administration ("FDA") has lifted the Partial Clinical Hold on the Company's Phase 1 multiple ascending dose clinical study of RGLS4326 for the treatment of autosomal dominant polycystic kidney disease (ADPKD) (the "MAD study"). The Company plans to recommence the MAD study in the first quarter of 2020. With the Partial Clinical Hold on the MAD study lifted, the Company is also planning to enroll patients with ADPKD in an additional short-term dosing study in the second half of 2020 to evaluate RGLS4326 for safety, pharmacokinetics, and biomarkers of pharmacodynamic activity as part of its comprehensive Phase 1b program.

  • Regulus Therapeutics to Present at the Stifel Healthcare Conference
    PR Newswire

    Regulus Therapeutics to Present at the Stifel Healthcare Conference

    LA JOLLA, Calif., Nov. 18, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that Jay Hagan, President and Chief Executive Officer of Regulus, will present a company overview at the Stifel Healthcare Conference in New York City on Wednesday, November 20, 2019. The company overview will include an update on RGLS4326 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and the Company's recent submission to FDA in response to the Partial Clinical Hold. ADPKD, caused by the mutations in the PKD1 or PKD2 genes, is among the most common human monogenic disorders and a leading cause of end-stage renal disease.

  • Analysts Are Upgrading Regulus Therapeutics Inc. After Its Latest Results
    Simply Wall St.

    Analysts Are Upgrading Regulus Therapeutics Inc. After Its Latest Results

    Regulus Therapeutics Inc. (NASDAQ:RGLS) shares fell 7.3% to US$0.64 in the week since its latest quarterly results...

  • Regulus (RGLS) Reports Q3 Loss, Lags Revenue Estimates
    Zacks

    Regulus (RGLS) Reports Q3 Loss, Lags Revenue Estimates

    Regulus (RGLS) delivered earnings and revenue surprises of 10.34% and -10.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Regulus Therapeutics Reports Third Quarter 2019 Financial Results and Recent Updates
    PR Newswire

    Regulus Therapeutics Reports Third Quarter 2019 Financial Results and Recent Updates

    Receipt of Final Reports from the Chronic Toxicity Studies for Submission of Complete Response to Reinitiate the Multiple Ascending Dose Clinical Study for RGLS4326 Appointment of Cris Calsada as New Chief ...

  • Regulus (RGLS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
    Zacks

    Regulus (RGLS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

    Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Regulus Therapeutics Presents Preclinical Data Identifying RGLS4326 as a Potential Disease-Modifying Treatment for Autosomal Dominant Polycystic Kidney Disease at OTS Annual Meeting
    PR Newswire

    Regulus Therapeutics Presents Preclinical Data Identifying RGLS4326 as a Potential Disease-Modifying Treatment for Autosomal Dominant Polycystic Kidney Disease at OTS Annual Meeting

    LA JOLLA, Calif., Oct. 16, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it presented preclinical data that identifies RGLS4326, a first-in-class anti-miR-17 oligonucleotide, as a potential disease-modifying treatment for autosomal dominant polycystic kidney disease (ADPKD) at the Oligonucleotide Therapeutics Society (OTS) Annual Meeting held October 13-16, 2019 in Munich, Germany. "We are pleased to have made a presentation of our RGLS4326 preclinical data during this year's OTS meeting and the unique mechanism of targeting miR-17 in order to treat patients with ADPKD," said Jay Hagan, President and Chief Executive Officer of Regulus.

  • Some Regulus Therapeutics (NASDAQ:RGLS) Shareholders Have Copped A 99% Share Price Wipe Out
    Simply Wall St.

    Some Regulus Therapeutics (NASDAQ:RGLS) Shareholders Have Copped A 99% Share Price Wipe Out

    Regulus Therapeutics Inc. (NASDAQ:RGLS) shareholders will doubtless be very grateful to see the share price up 43% in...

  • Regulus Therapeutics Announces Publication in Nature Communications Identifying RGLS4326 as a Potential Promising Treatment for ADPKD
    PR Newswire

    Regulus Therapeutics Announces Publication in Nature Communications Identifying RGLS4326 as a Potential Promising Treatment for ADPKD

    LA JOLLA, Calif., Sept. 12, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that Nature Communications has published an article entitled, "Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease." The article highlights preclinical research that identifies RGLS4326, a first-in-class anti-miR-17 oligonucleotide, as a potential disease-modifying treatment for autosomal dominant polycystic kidney disease (ADPKD) and can be found on-line at http://www.nature.com/ncomms.

  • Regulus Therapeutics to Present at the H.C. Wainwright Global Investment Conference
    PR Newswire

    Regulus Therapeutics to Present at the H.C. Wainwright Global Investment Conference

    Regulus Therapeutics Inc. (RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs.  Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field.  Regulus maintains its corporate headquarters in La Jolla, CA.  For more information, please visit http://www.regulusrx.com. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements.

  • Regulus Therapeutics to Present at the Wells Fargo Healthcare Conference
    PR Newswire

    Regulus Therapeutics to Present at the Wells Fargo Healthcare Conference

    Regulus Therapeutics Inc. (RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs.  Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field.  Regulus maintains its corporate headquarters in La Jolla, CA.  For more information, please visit http://www.regulusrx.com. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements.

  • Regulus (RGLS) Reports Q2 Loss, Misses Revenue Estimates
    Zacks

    Regulus (RGLS) Reports Q2 Loss, Misses Revenue Estimates

    Regulus (RGLS) delivered earnings and revenue surprises of 50.00% and -99.28%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Regulus Therapeutics Reports Second Quarter 2019 Financial Results and Recent Updates
    PR Newswire

    Regulus Therapeutics Reports Second Quarter 2019 Financial Results and Recent Updates

    Private Financing: In May 2019, the Company closed the first tranche of its $41.8 million private placement of equity (the "Private Placement"). The Company received net proceeds of approximately $15.7 million from the first tranche, after deducting placement agent fees and other offering expenses.

  • What Percentage Of Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Do Insiders Own?
    Simply Wall St.

    What Percentage Of Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Do Insiders Own?

    A look at the shareholders of Regulus Therapeutics Inc. (NASDAQ:RGLS) can tell us which group is most powerful...

  • Will Regulus (RGLS) Report Negative Q2 Earnings? What You Should Know
    Zacks

    Will Regulus (RGLS) Report Negative Q2 Earnings? What You Should Know

    Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Regulus Therapeutics Appoints Cris Calsada as Chief Financial Officer
    PR Newswire

    Regulus Therapeutics Appoints Cris Calsada as Chief Financial Officer

    LA JOLLA, Calif., July 30, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the appointment of Cris Calsada as its new Chief Financial Officer effective August 30, 2019. Ms. Calsada joins Regulus from Sanifit where she has served as Chief Financial Officer since December 2017.  Ms. Calsada brings to Regulus' senior management team a unique combination of financial, operational and managerial experience. Earlier in her career, she practiced as a certified public accountant.

  • Benzinga

    The Daily Biotech Pulse: Setback For Bristol-Myers Squibb, Gemphire Explodes, Lilly's Nasal Low Blood Sugar Drug

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 24) Acasti Pharma Inc (NASDAQ: ACST ) Cardiovascular Systems ...

  • Benzinga

    The Daily Biotech Pulse: Jounce Jumps On Licensing Deal, Regulus Hit With Partial Clinical Hold, Genomic Health Added to S&P SmallCap Index

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 23) Akero Therapeutics Inc (NASDAQ: AKRO ) Mirum Pharmaceuticals ...